CA2465274A1 - Analyse de parametres multiples d'acides nucleiques et de caracteristiques morphologiques d'ensemble sur le meme echantillon - Google Patents
Analyse de parametres multiples d'acides nucleiques et de caracteristiques morphologiques d'ensemble sur le meme echantillon Download PDFInfo
- Publication number
- CA2465274A1 CA2465274A1 CA002465274A CA2465274A CA2465274A1 CA 2465274 A1 CA2465274 A1 CA 2465274A1 CA 002465274 A CA002465274 A CA 002465274A CA 2465274 A CA2465274 A CA 2465274A CA 2465274 A1 CA2465274 A1 CA 2465274A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- rna
- cytoplasmic
- combinations
- accomplished
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 66
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 66
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 66
- 230000000877 morphologic effect Effects 0.000 title claims description 11
- 238000011527 multiparameter analysis Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 340
- 238000000034 method Methods 0.000 claims abstract description 231
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 196
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 177
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 85
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 61
- 230000003321 amplification Effects 0.000 claims abstract description 60
- 210000004369 blood Anatomy 0.000 claims abstract description 47
- 239000008280 blood Substances 0.000 claims abstract description 47
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 238000002493 microarray Methods 0.000 claims abstract description 18
- 238000012790 confirmation Methods 0.000 claims abstract description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 212
- 238000004458 analytical method Methods 0.000 claims description 138
- 230000001086 cytosolic effect Effects 0.000 claims description 100
- 239000013615 primer Substances 0.000 claims description 85
- 230000014509 gene expression Effects 0.000 claims description 61
- 108020004414 DNA Proteins 0.000 claims description 58
- 238000011282 treatment Methods 0.000 claims description 41
- 239000002299 complementary DNA Substances 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 239000003381 stabilizer Substances 0.000 claims description 31
- 230000001413 cellular effect Effects 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 26
- 238000001962 electrophoresis Methods 0.000 claims description 26
- 239000012038 nucleophile Substances 0.000 claims description 26
- 108091093088 Amplicon Proteins 0.000 claims description 24
- 210000003470 mitochondria Anatomy 0.000 claims description 24
- 229930182490 saponin Natural products 0.000 claims description 24
- 150000007949 saponins Chemical class 0.000 claims description 24
- 102000035195 Peptidases Human genes 0.000 claims description 23
- 108091005804 Peptidases Proteins 0.000 claims description 23
- 238000000137 annealing Methods 0.000 claims description 23
- 239000011324 bead Substances 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 22
- 235000019833 protease Nutrition 0.000 claims description 21
- 108091092330 cytoplasmic RNA Proteins 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 150000001299 aldehydes Chemical class 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 108010067770 Endopeptidase K Proteins 0.000 claims description 17
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 17
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 16
- 230000029087 digestion Effects 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 16
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims description 15
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 238000000636 Northern blotting Methods 0.000 claims description 14
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000010186 staining Methods 0.000 claims description 14
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 13
- 238000004587 chromatography analysis Methods 0.000 claims description 13
- 229920002866 paraformaldehyde Polymers 0.000 claims description 13
- 239000008191 permeabilizing agent Substances 0.000 claims description 13
- 239000000377 silicon dioxide Substances 0.000 claims description 13
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 11
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 11
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 10
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 10
- 238000001818 capillary gel electrophoresis Methods 0.000 claims description 10
- 230000006862 enzymatic digestion Effects 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 238000003491 array Methods 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 238000004949 mass spectrometry Methods 0.000 claims description 9
- 230000002441 reversible effect Effects 0.000 claims description 9
- 239000003155 DNA primer Substances 0.000 claims description 8
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 8
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 230000008263 repair mechanism Effects 0.000 claims description 8
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims description 7
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 7
- 239000007983 Tris buffer Substances 0.000 claims description 7
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims description 7
- 229940015043 glyoxal Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 101150079601 recA gene Proteins 0.000 claims description 7
- 230000006798 recombination Effects 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims description 7
- 108010051815 Glutamyl endopeptidase Proteins 0.000 claims description 6
- 108020003217 Nuclear RNA Proteins 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 108010059712 Pronase Proteins 0.000 claims description 6
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims description 6
- 238000003277 amino acid sequence analysis Methods 0.000 claims description 6
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims description 6
- 238000004817 gas chromatography Methods 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 108091064355 mitochondrial RNA Proteins 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 5
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 238000005481 NMR spectroscopy Methods 0.000 claims description 4
- 230000007717 exclusion Effects 0.000 claims description 4
- 238000010348 incorporation Methods 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- 210000003850 cellular structure Anatomy 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims 10
- 241000796533 Arna Species 0.000 claims 9
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical group N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims 8
- 241000269627 Amphiuma means Species 0.000 claims 6
- 239000012629 purifying agent Substances 0.000 claims 4
- 108091093105 Nuclear DNA Proteins 0.000 claims 3
- 238000012594 liquid chromatography nuclear magnetic resonance Methods 0.000 claims 2
- 238000012197 amplification kit Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 abstract description 53
- 238000003556 assay Methods 0.000 abstract description 16
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 230000006872 improvement Effects 0.000 abstract description 8
- 238000012544 monitoring process Methods 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 201000009030 Carcinoma Diseases 0.000 abstract description 5
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 108091005461 Nucleic proteins Proteins 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 238000007403 mPCR Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 94
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 51
- 238000010240 RT-PCR analysis Methods 0.000 description 43
- 210000000265 leukocyte Anatomy 0.000 description 40
- 239000012528 membrane Substances 0.000 description 34
- 108020005544 Antisense RNA Proteins 0.000 description 33
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 33
- 108010066302 Keratin-19 Proteins 0.000 description 33
- 239000003184 complementary RNA Substances 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 31
- 239000003153 chemical reaction reagent Substances 0.000 description 31
- 230000008823 permeabilization Effects 0.000 description 31
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 30
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000000834 fixative Substances 0.000 description 25
- 238000010839 reverse transcription Methods 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 230000003834 intracellular effect Effects 0.000 description 22
- 235000017709 saponins Nutrition 0.000 description 21
- 238000002123 RNA extraction Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 238000011084 recovery Methods 0.000 description 20
- 238000002955 isolation Methods 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 17
- 239000011554 ferrofluid Substances 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 15
- 102100038358 Prostate-specific antigen Human genes 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 14
- 102100032187 Androgen receptor Human genes 0.000 description 13
- 108010080146 androgen receptors Proteins 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 108090001101 Hepsin Proteins 0.000 description 11
- 102000004989 Hepsin Human genes 0.000 description 11
- 108050003189 SH2B adapter protein 1 Proteins 0.000 description 11
- 239000011543 agarose gel Substances 0.000 description 11
- 108091092328 cellular RNA Proteins 0.000 description 11
- 238000010195 expression analysis Methods 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 238000000326 densiometry Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 8
- 229960005542 ethidium bromide Drugs 0.000 description 8
- -1 hRNA) Proteins 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 210000003463 organelle Anatomy 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000003260 vortexing Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 101150084967 EPCAM gene Proteins 0.000 description 6
- 108010000817 Leuprolide Proteins 0.000 description 6
- 108010053584 alpha-Globins Proteins 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 6
- 229940087857 lupron Drugs 0.000 description 6
- 230000036457 multidrug resistance Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 6
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000006148 magnetic separator Substances 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 108020004463 18S ribosomal RNA Proteins 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 101000739159 Homo sapiens Mammaglobin-A Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 4
- 108010070511 Keratin-8 Proteins 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
- 102100037273 Mammaglobin-A Human genes 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 4
- 101710088644 Prolactin-inducible protein Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 239000000980 acid dye Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000003196 chaotropic effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical class O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 235000002020 sage Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000012134 supernatant fraction Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 210000000633 nuclear envelope Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000003161 ribonuclease inhibitor Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- AXNVHPCVMSNXNP-IVKVKCDBSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,9r,10r,12as,14ar,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(e)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(C[C@H]14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AXNVHPCVMSNXNP-IVKVKCDBSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- FIAFBLDKTGXKHY-UHFFFAOYSA-N C(C)(C)(CC(C)(C)C)CC(O)(OCC)OC1=CC=CC=C1 Chemical compound C(C)(C)(CC(C)(C)C)CC(O)(OCC)OC1=CC=CC=C1 FIAFBLDKTGXKHY-UHFFFAOYSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 101710147336 Choline/ethanolamine kinase Proteins 0.000 description 2
- 102100022785 Creatine kinase B-type Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 2
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 2
- 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 description 2
- 102000000820 Enterotoxin Receptors Human genes 0.000 description 2
- 108010001687 Enterotoxin Receptors Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 2
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 description 2
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 2
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 2
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 2
- 102100025758 Keratin, type II cytoskeletal 4 Human genes 0.000 description 2
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 2
- 108010066370 Keratin-20 Proteins 0.000 description 2
- 108010070553 Keratin-5 Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 108700036248 MT-RNR1 Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 102000007298 Mucin-1 Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000005497 Thymidylate Synthase Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 2
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000003322 phosphorimaging Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012313 reversal agent Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 102100024090 Aldo-keto reductase family 1 member C3 Human genes 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 1
- 101150092780 GSP1 gene Proteins 0.000 description 1
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 101000774835 Heteractis crispa PI-stichotoxin-Hcr2o Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 description 1
- 101000840551 Homo sapiens Hexokinase-2 Proteins 0.000 description 1
- 101001050577 Homo sapiens Kinesin-like protein KIF2A Proteins 0.000 description 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
- 101001026214 Homo sapiens Potassium voltage-gated channel subfamily A member 5 Proteins 0.000 description 1
- 101001048456 Homo sapiens Protein Hook homolog 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010070921 Keratin-4 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102100023426 Kinesin-like protein KIF2A Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010065942 Prostaglandin-F synthase Proteins 0.000 description 1
- 102100029500 Prostasin Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 101000605535 Rattus norvegicus Tonin Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 description 1
- 101710180672 Regulator of MON1-CCZ1 complex Proteins 0.000 description 1
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 1
- 101100393821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GSP2 gene Proteins 0.000 description 1
- 101150077804 TIMP1 gene Proteins 0.000 description 1
- 101150117918 Tacstd2 gene Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 101150021063 Timp2 gene Proteins 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 238000011298 ablation treatment Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- AXNVHPCVMSNXNP-BEJCRFBNSA-N beta-escin Natural products CC=C(/C)C(=O)O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)C[C@@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@H]6O[C@@H]([C@H](O[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@@H]6O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)C(=O)O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C AXNVHPCVMSNXNP-BEJCRFBNSA-N 0.000 description 1
- 229940093314 beta-escin Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001738 cardenolides Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000006846 excision repair Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108010031970 prostasin Proteins 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000007859 qualitative PCR Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102220047090 rs6152 Human genes 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003196 serial analysis of gene expression Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000003537 structural cell Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un dosage hautement sensible qui utilise une technique d'amplification amorcée spécifique du gène de bibliothèques d'ARNm issus de cellules rares et de transcrits rares trouvés dans le sang. Ce dosage permet de détecter des ARNm (10 copies /cellule) trouvés dans une à dix cellules isolées via un enrichissement immunomagnétique. Ce dosage constitue une amélioration par rapport à la PCR multiplex et permet de détecter efficacement des séquences de codage rares de cellules de carcinome circulant dans le sang. Ces techniques conviennent pour établir le profil de cellules isolées issues de tissus ou de fluides anatomiques et elles servent d'auxiliaire pour un diagnostic clinique de divers carcinomes, notamment dans la détection au stade précoce et dans la classification des cellules tumorales circulant. La surveillance des profils d'acide nucléique et de protéine de cellules dans des formats soit classiques, soit de jeu ordonné de microéchantillons, facilite la gestion d'intervention thérapeutique comprenant la classification par stades, la surveillance de la réponse à la thérapie, la confirmation de rémission et la détection de régression.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33066901P | 2001-10-26 | 2001-10-26 | |
US60/330,669 | 2001-10-26 | ||
US36994502P | 2002-04-04 | 2002-04-04 | |
US60/369,945 | 2002-04-04 | ||
PCT/US2002/034397 WO2003035894A2 (fr) | 2001-10-26 | 2002-10-28 | Analyse de parametres multiples d'acides nucleiques et de caracteristiques morphologiques d'ensemble sur le meme echantillon |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2465274A1 true CA2465274A1 (fr) | 2003-05-01 |
Family
ID=26987390
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002465288A Abandoned CA2465288A1 (fr) | 2001-10-26 | 2002-10-28 | Analyse a parametres multiples d'acides nucleiques complets et de caracteristiques morphologiques sur le meme echantillon |
CA002465274A Abandoned CA2465274A1 (fr) | 2001-10-26 | 2002-10-28 | Analyse de parametres multiples d'acides nucleiques et de caracteristiques morphologiques d'ensemble sur le meme echantillon |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002465288A Abandoned CA2465288A1 (fr) | 2001-10-26 | 2002-10-28 | Analyse a parametres multiples d'acides nucleiques complets et de caracteristiques morphologiques sur le meme echantillon |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP1438419A2 (fr) |
JP (1) | JP2005507997A (fr) |
KR (1) | KR20040047971A (fr) |
CN (1) | CN1610752A (fr) |
AU (1) | AU2002360305A1 (fr) |
BR (1) | BR0213520A (fr) |
CA (2) | CA2465288A1 (fr) |
IL (1) | IL161357A0 (fr) |
WO (2) | WO2003035894A2 (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6913697B2 (en) | 2001-02-14 | 2005-07-05 | Science & Technology Corporation @ Unm | Nanostructured separation and analysis devices for biological membranes |
US8986944B2 (en) | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
US7318902B2 (en) | 2002-02-04 | 2008-01-15 | Colorado School Of Mines | Laminar flow-based separations of colloidal and cellular particles |
ES2375724T3 (es) | 2002-09-27 | 2012-03-05 | The General Hospital Corporation | Dispositivo microflu�?dico para seperación de células y sus usos. |
CA2542656A1 (fr) * | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | Systeme d'essai qrt-pcr pour le profilage d'expression genetique |
US7332597B2 (en) | 2004-06-28 | 2008-02-19 | University Of Kentucky Research Foundation | Primers and probe to identify mycobacterium tuberculosis complex |
ITBO20040420A1 (it) | 2004-07-07 | 2004-10-07 | Type S R L | Macchina per taglio e formatura di piattine metalliche |
DE102005013261A1 (de) * | 2005-03-22 | 2006-09-28 | Adnagen Ag | Reagenz und Verfahren zur Verhinderung der zeitabhängigen Expression in biologischen Zellen |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
DE102005029808A1 (de) * | 2005-06-27 | 2007-01-04 | Siemens Ag | Trägermaterial, Verfahren zu seiner Herstellung und Verwendung |
ITBO20050481A1 (it) | 2005-07-19 | 2007-01-20 | Silicon Biosystems S R L | Metodo ed apparato per la manipolazione e/o l'individuazione di particelle |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
KR101446626B1 (ko) | 2005-09-02 | 2014-10-06 | 도레이 카부시키가이샤 | 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법 |
US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
US9127302B2 (en) | 2005-09-20 | 2015-09-08 | Janssen Diagnostics, Llc | System for the detection and enumeration of suspect target cells in a mixed cell population |
ITBO20050646A1 (it) | 2005-10-26 | 2007-04-27 | Silicon Biosystem S R L | Metodo ed apparato per la caratterizzazione ed il conteggio di particelle |
US9878326B2 (en) | 2007-09-26 | 2018-01-30 | Colorado School Of Mines | Fiber-focused diode-bar optical trapping for microfluidic manipulation |
US9487812B2 (en) | 2012-02-17 | 2016-11-08 | Colorado School Of Mines | Optical alignment deformation spectroscopy |
US9885644B2 (en) | 2006-01-10 | 2018-02-06 | Colorado School Of Mines | Dynamic viscoelasticity as a rapid single-cell biomarker |
US8119976B2 (en) | 2007-07-03 | 2012-02-21 | Colorado School Of Mines | Optical-based cell deformability |
ITTO20060226A1 (it) | 2006-03-27 | 2007-09-28 | Silicon Biosystem S P A | Metodo ed apparato per il processamento e o l'analisi e o la selezione di particelle, in particolare particelle biologiche |
CA2647843A1 (fr) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection de proteines dans des cellules neoplasiques en circulation |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2589668A1 (fr) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Analyse de cellules rares utilisant la division d'échantillons et les marqueurs d'ADN |
WO2007147074A2 (fr) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Utilisation de génotypage snp fortement parallèle pour diagnostic fœtal |
EP2041299A4 (fr) | 2006-07-14 | 2010-01-13 | Aviva Biosciences Corp | Procedes et compositions servant a detecter des cellules rares dans un echantillon biologique |
JP4926812B2 (ja) * | 2007-02-01 | 2012-05-09 | シスメックス株式会社 | 血球分析装置および体液分析方法 |
US10722250B2 (en) | 2007-09-04 | 2020-07-28 | Colorado School Of Mines | Magnetic-field driven colloidal microbots, methods for forming and using the same |
ITTO20070771A1 (it) | 2007-10-29 | 2009-04-30 | Silicon Biosystems Spa | Metodo e apparato per la identificazione e manipolazione di particelle |
LT2334812T (lt) | 2008-09-20 | 2017-04-25 | The Board Of Trustees Of The Leland Stanford Junior University | Neinvazinis fetalinės aneuploidijos diagnozavimas sekvenavimu |
IT1391619B1 (it) | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
US10895575B2 (en) | 2008-11-04 | 2021-01-19 | Menarini Silicon Biosystems S.P.A. | Method for identification, selection and analysis of tumour cells |
CA2782123C (fr) | 2009-03-17 | 2017-05-02 | Silicon Biosystems S.P.A. | Dispositif microfluidique |
JP5729904B2 (ja) | 2009-06-02 | 2015-06-03 | キヤノン株式会社 | 細胞から蛋白質、dna、rnaを調製する方法 |
CN102575244B (zh) | 2009-09-17 | 2015-07-22 | Jsr株式会社 | 抗生物素蛋白与生物素衍生物的解离方法以及解离剂 |
US8722328B2 (en) * | 2010-01-04 | 2014-05-13 | Qiagen Gaithersburg, Inc. | Methods, compositions, and kits for recovery of nucleic acids or proteins from fixed tissue samples |
US9273347B2 (en) | 2010-09-10 | 2016-03-01 | Bio-Rad Laboratories, Inc. | Detection of RNA-interacting regions in DNA |
CN102565404B (zh) * | 2010-12-24 | 2014-04-16 | 牛刚 | 一种检测血液中游离大肠癌细胞标志物的试剂盒 |
CN102156164B (zh) * | 2011-01-13 | 2012-12-12 | 北京肿瘤医院 | 核仁磷酸蛋白可变剪接体的质谱鉴定方法和胃癌诊断试剂盒 |
CN102109525B (zh) * | 2011-01-26 | 2013-10-16 | 牛刚 | 一种检测血液中游离乳腺癌细胞标志物的试剂盒 |
WO2012112606A1 (fr) | 2011-02-15 | 2012-08-23 | Bio-Rad Laboratories, Inc. | Détection de méthylation dans une sous-population d'adn génomique |
US20120252038A1 (en) * | 2011-04-01 | 2012-10-04 | Chianese David A | Steroid receptor assays |
EP2739752B1 (fr) * | 2011-08-03 | 2017-07-19 | Bio-Rad Laboratories, Inc. | Filtration de petits acides nucléiques à l'aide de cellules perméabilisées |
ITTO20110990A1 (it) | 2011-10-28 | 2013-04-29 | Silicon Biosystems Spa | Metodo ed apparato per l'analisi ottica di particelle a basse temperature |
ITBO20110766A1 (it) | 2011-12-28 | 2013-06-29 | Silicon Biosystems Spa | Dispositivi, apparato, kit e metodo per il trattamento di un campione biologico |
WO2014067528A1 (fr) * | 2012-10-29 | 2014-05-08 | Arcedi Biotech Aps | Enrichissement et détection améliorés de cellules sanguines rares |
US9857361B2 (en) | 2013-03-15 | 2018-01-02 | Iris International, Inc. | Flowcell, sheath fluid, and autofocus systems and methods for particle analysis in urine samples |
ES2658692T3 (es) | 2013-03-15 | 2018-03-12 | Iris International, Inc. | Método y composición para teñir y procesar una muestra de orina |
EP3670663A1 (fr) * | 2014-02-28 | 2020-06-24 | Gen-Probe Incorporated | Procédé pour isoler l'acide nucléique d'échantillons dans des conservateurs de cytologie aqueux contenant du formaldéhyde |
US9771571B2 (en) | 2014-02-28 | 2017-09-26 | Gen-Probe Incorporated | Method of isolating nucleic acid from specimens in liquid-based cytology preservatives containing formaldehyde |
US9771572B2 (en) | 2014-02-28 | 2017-09-26 | Gen-Probe Incorporated | Method of isolating nucleic acid from specimens in liquid-based cytology preservatives containing formaldehyde |
JP2014158468A (ja) * | 2014-03-05 | 2014-09-04 | Clinical Genomics Pty Ltd | 検出方法 |
KR20170135834A (ko) * | 2015-02-10 | 2017-12-08 | 일루미나, 인코포레이티드 | 세포 성분을 분석하기 위한 방법 및 조성물 |
US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
US10282588B2 (en) * | 2016-06-09 | 2019-05-07 | Siemens Healthcare Gmbh | Image-based tumor phenotyping with machine learning from synthetic data |
CN110456034B (zh) * | 2018-05-07 | 2022-07-22 | 上海市第十人民医院 | 一种循环肿瘤细胞的检测方法 |
CN109402240B (zh) * | 2019-01-08 | 2020-08-25 | 圣湘生物科技股份有限公司 | 核酸释放剂、核酸pcr扩增方法和pcr扩增试剂盒 |
WO2023080601A1 (fr) * | 2021-11-05 | 2023-05-11 | 고려대학교 세종산학협력단 | Procédé et dispositif de diagnostic de maladie faisant appel à une technologie d'imagerie par ombre sans lentille basée sur l'apprentissage machine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929556A (en) * | 1986-02-06 | 1990-05-29 | The Dow Chemical Company | Enzyme immobilization with polysulfonium salts |
US5346994A (en) * | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
CA2262403C (fr) * | 1995-07-31 | 2011-09-20 | Urocor, Inc. | Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate |
US6329179B1 (en) * | 1996-03-26 | 2001-12-11 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
US6156564A (en) * | 1996-06-07 | 2000-12-05 | The United States Of America As Represented By The Department Of Health And Human Services | Cellular apoptosis susceptibility protein (CSP) and antisense CSP |
IL137802A0 (en) * | 1998-02-12 | 2001-10-31 | Immunivest Corp | A method and kit for detecting rare cells in a mixed cell population |
US6156515A (en) * | 1999-02-09 | 2000-12-05 | Urocor, Inc. | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
US6358697B2 (en) * | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
-
2002
- 2002-10-28 CN CNA028261313A patent/CN1610752A/zh active Pending
- 2002-10-28 JP JP2003538395A patent/JP2005507997A/ja not_active Ceased
- 2002-10-28 WO PCT/US2002/034397 patent/WO2003035894A2/fr not_active Application Discontinuation
- 2002-10-28 BR BRPI0213520-5A patent/BR0213520A/pt unknown
- 2002-10-28 CA CA002465288A patent/CA2465288A1/fr not_active Abandoned
- 2002-10-28 KR KR10-2004-7006181A patent/KR20040047971A/ko not_active Application Discontinuation
- 2002-10-28 EP EP02795565A patent/EP1438419A2/fr not_active Withdrawn
- 2002-10-28 CA CA002465274A patent/CA2465274A1/fr not_active Abandoned
- 2002-10-28 WO PCT/US2002/034570 patent/WO2003035895A2/fr not_active Application Discontinuation
- 2002-10-28 EP EP02795554A patent/EP1438398A2/fr not_active Withdrawn
- 2002-10-28 IL IL16135702A patent/IL161357A0/xx unknown
- 2002-10-28 AU AU2002360305A patent/AU2002360305A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003035894A3 (fr) | 2003-12-04 |
KR20040047971A (ko) | 2004-06-05 |
WO2003035894A2 (fr) | 2003-05-01 |
WO2003035895A2 (fr) | 2003-05-01 |
CN1610752A (zh) | 2005-04-27 |
WO2003035895A3 (fr) | 2004-01-08 |
EP1438419A2 (fr) | 2004-07-21 |
IL161357A0 (en) | 2004-09-27 |
BR0213520A (pt) | 2006-05-23 |
CA2465288A1 (fr) | 2003-05-01 |
AU2002360305A1 (en) | 2003-05-06 |
JP2005507997A (ja) | 2005-03-24 |
EP1438398A2 (fr) | 2004-07-21 |
WO2003035894A8 (fr) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060008807A1 (en) | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample | |
CA2465274A1 (fr) | Analyse de parametres multiples d'acides nucleiques et de caracteristiques morphologiques d'ensemble sur le meme echantillon | |
KR102088381B1 (ko) | 압타머-기반 다중 검정법 | |
JP7094880B2 (ja) | 代表診断法 | |
JP5763545B2 (ja) | ホルマリン固定組織からの種々の生体分子の並行抽出 | |
CN109777872B (zh) | 肺癌中的t细胞亚群及其特征基因 | |
EP2638176B1 (fr) | Enrichissement et identification de cellules foetales dans le sang maternel et ligands pour cette utilisation | |
EP2385993B1 (fr) | Analyse génétique de cellules | |
WO2003078662A1 (fr) | Profilage d'expression genique dans des tissus tumoraux ponctionnes | |
EP3274476A1 (fr) | Analyse numérique de cellules tumorales circulantes dans des échantillons de sang | |
Bracht et al. | Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform | |
EP3358020B1 (fr) | Système de test de diagnostic pour détection spécifique, sensible et reproductible d'acides nucléiques en circulation dans le sang total | |
Jacobson et al. | Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer | |
CN107367618B (zh) | 与胎儿绒毛外滋养层细胞测定有关的方法和组合物 | |
US20180128832A1 (en) | Proteogenomic analysis system and methods | |
KR102623368B1 (ko) | 엑소좀 유래 miRNA를 이용한 아토피성 피부염 상관 스트레스 진단기술 | |
US11155852B2 (en) | RT-qPCR analysis of micro-dissected material from stained FFPET section | |
EP3385392A1 (fr) | Procédé d'analyse de l'expression d'un ou de plusieurs molécules d'arn de biomarqueur | |
AU2002360316A1 (en) | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample | |
US20100323354A1 (en) | Means and methods for the detection and isolation of fetal and embryonic cells and nucleic acid from maternal body fluid | |
Van Langendonckt et al. | Identification of novel antigens in blood vessels in rectovaginal endometriosis | |
EP3910070A1 (fr) | Procédé d'analyse de l'expression d'une ou plusieurs molécules d'arn de biomarqueur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20061030 |